Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisk’s Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the first-ever head-to-head trial were presented at the European Congress on Obesity and confirmed Zepbound's superior efficacy.
Previously reported in December, the trial had already shown that Zepbound led to 47% more weight loss than Wegovy. According to full data released Sunday, nearly 25% more participants lost over 15% of their body weight with Zepbound compared to Wegovy.
The study revealed Zepbound users experienced an average waist reduction of 18.4 centimeters, versus 13 centimeters for those on Wegovy. Zepbound, which mimics two gut hormones, has a dual mechanism of action, while Wegovy targets just one. This biological advantage may explain the enhanced weight loss results.
Both drugs had previously received U.S. FDA approval based on separate clinical trials—Zepbound achieved over 22% weight loss after 72 weeks, while Wegovy showed 15% loss after 68 weeks. The obesity drug market is expected to surpass $150 billion annually by the next decade, making these results crucial as Eli Lilly seeks broader insurance coverage.
The new data comes shortly after CVS Health (NYSE:CVS) dropped Zepbound from some reimbursement lists in favor of Wegovy. However, these trial findings may bolster Lilly’s position in payer negotiations and strengthen its commercial appeal.
With growing demand for effective weight-loss treatments, Zepbound’s performance positions it as a formidable competitor in the fast-growing obesity drug market, challenging Wegovy’s dominance with robust clinical backing and enhanced patient outcomes.
